Primary radiation therapy for head-and-neck cancer in the setting of human immunodeficiency virus

Emily A. Klein, Michael Guiou, D Gregory Farwell, Quang Luu, Derick H Lau, Kerri Stuart, Andrew T M Vaughan, Srinivasan Vijayakumar, Allen M. Chen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: To analyze outcomes after radiation therapy for head-and-neck cancer among a cohort of patients with human immunodeficiency virus (HIV). Methods and Materials: The medical records of 12 patients with serologic evidence of HIV who subsequently underwent radiation therapy to a median dose of 68 Gy (range, 64-72 Gy) for newly diagnosed squamous cell carcinoma of the head and neck were reviewed. Six patients (50%) received concurrent chemotherapy. Intensity-modulated radiotherapy was used in 6 cases (50%). All patients had a Karnofsky performance status of 80 or 90. Nine patients (75%) were receiving antiretroviral therapies at the time of treatment, and the median CD4 count was 460 (range, 266-800). Toxicity was graded according to the Radiation Therapy Oncology Group / European Organization for the Treatment of Cancer toxicity criteria. Results: The 3-year estimates of overall survival and local-regional control were 78% and 92%, respectively. Acute Grade 3+ toxicity occurred in 7 patients (58%), the most common being confluent mucositis (5 patients) and moist skin desquamation (4 patients). Two patients experienced greater than 10% weight loss, and none experienced more than 15% weight loss from baseline. Five patients (42%) experienced treatment breaks in excess of 10 cumulative days, although none required hospitalization. There were no treatment-related fatalities. Conclusions: Radiation therapy for head-and-neck cancer seems to be relatively well tolerated among appropriately selected patients with HIV. The observed rates of toxicity were comparable to historical controls without HIV.

Original languageEnglish (US)
Pages (from-to)60-64
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume79
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

human immunodeficiency virus
Head and Neck Neoplasms
radiation therapy
Radiotherapy
cancer
HIV
toxicity
Weight Loss
Therapeutics
Karnofsky Performance Status
Intensity-Modulated Radiotherapy
Mucositis
Radiation Oncology
chemotherapy
CD4 Lymphocyte Count
Medical Records
grade
therapy
Hospitalization

Keywords

  • Head-and-neck cancer
  • Human immunodeficiency virus
  • Immunosuppression
  • Radiotherapy
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Primary radiation therapy for head-and-neck cancer in the setting of human immunodeficiency virus. / Klein, Emily A.; Guiou, Michael; Farwell, D Gregory; Luu, Quang; Lau, Derick H; Stuart, Kerri; Vaughan, Andrew T M; Vijayakumar, Srinivasan; Chen, Allen M.

In: International Journal of Radiation Oncology Biology Physics, Vol. 79, No. 1, 01.01.2011, p. 60-64.

Research output: Contribution to journalArticle

Klein, Emily A. ; Guiou, Michael ; Farwell, D Gregory ; Luu, Quang ; Lau, Derick H ; Stuart, Kerri ; Vaughan, Andrew T M ; Vijayakumar, Srinivasan ; Chen, Allen M. / Primary radiation therapy for head-and-neck cancer in the setting of human immunodeficiency virus. In: International Journal of Radiation Oncology Biology Physics. 2011 ; Vol. 79, No. 1. pp. 60-64.
@article{19b43ccd425842daa79de52d7b2aac0a,
title = "Primary radiation therapy for head-and-neck cancer in the setting of human immunodeficiency virus",
abstract = "Purpose: To analyze outcomes after radiation therapy for head-and-neck cancer among a cohort of patients with human immunodeficiency virus (HIV). Methods and Materials: The medical records of 12 patients with serologic evidence of HIV who subsequently underwent radiation therapy to a median dose of 68 Gy (range, 64-72 Gy) for newly diagnosed squamous cell carcinoma of the head and neck were reviewed. Six patients (50{\%}) received concurrent chemotherapy. Intensity-modulated radiotherapy was used in 6 cases (50{\%}). All patients had a Karnofsky performance status of 80 or 90. Nine patients (75{\%}) were receiving antiretroviral therapies at the time of treatment, and the median CD4 count was 460 (range, 266-800). Toxicity was graded according to the Radiation Therapy Oncology Group / European Organization for the Treatment of Cancer toxicity criteria. Results: The 3-year estimates of overall survival and local-regional control were 78{\%} and 92{\%}, respectively. Acute Grade 3+ toxicity occurred in 7 patients (58{\%}), the most common being confluent mucositis (5 patients) and moist skin desquamation (4 patients). Two patients experienced greater than 10{\%} weight loss, and none experienced more than 15{\%} weight loss from baseline. Five patients (42{\%}) experienced treatment breaks in excess of 10 cumulative days, although none required hospitalization. There were no treatment-related fatalities. Conclusions: Radiation therapy for head-and-neck cancer seems to be relatively well tolerated among appropriately selected patients with HIV. The observed rates of toxicity were comparable to historical controls without HIV.",
keywords = "Head-and-neck cancer, Human immunodeficiency virus, Immunosuppression, Radiotherapy, Toxicity",
author = "Klein, {Emily A.} and Michael Guiou and Farwell, {D Gregory} and Quang Luu and Lau, {Derick H} and Kerri Stuart and Vaughan, {Andrew T M} and Srinivasan Vijayakumar and Chen, {Allen M.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.ijrobp.2009.10.042",
language = "English (US)",
volume = "79",
pages = "60--64",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Primary radiation therapy for head-and-neck cancer in the setting of human immunodeficiency virus

AU - Klein, Emily A.

AU - Guiou, Michael

AU - Farwell, D Gregory

AU - Luu, Quang

AU - Lau, Derick H

AU - Stuart, Kerri

AU - Vaughan, Andrew T M

AU - Vijayakumar, Srinivasan

AU - Chen, Allen M.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Purpose: To analyze outcomes after radiation therapy for head-and-neck cancer among a cohort of patients with human immunodeficiency virus (HIV). Methods and Materials: The medical records of 12 patients with serologic evidence of HIV who subsequently underwent radiation therapy to a median dose of 68 Gy (range, 64-72 Gy) for newly diagnosed squamous cell carcinoma of the head and neck were reviewed. Six patients (50%) received concurrent chemotherapy. Intensity-modulated radiotherapy was used in 6 cases (50%). All patients had a Karnofsky performance status of 80 or 90. Nine patients (75%) were receiving antiretroviral therapies at the time of treatment, and the median CD4 count was 460 (range, 266-800). Toxicity was graded according to the Radiation Therapy Oncology Group / European Organization for the Treatment of Cancer toxicity criteria. Results: The 3-year estimates of overall survival and local-regional control were 78% and 92%, respectively. Acute Grade 3+ toxicity occurred in 7 patients (58%), the most common being confluent mucositis (5 patients) and moist skin desquamation (4 patients). Two patients experienced greater than 10% weight loss, and none experienced more than 15% weight loss from baseline. Five patients (42%) experienced treatment breaks in excess of 10 cumulative days, although none required hospitalization. There were no treatment-related fatalities. Conclusions: Radiation therapy for head-and-neck cancer seems to be relatively well tolerated among appropriately selected patients with HIV. The observed rates of toxicity were comparable to historical controls without HIV.

AB - Purpose: To analyze outcomes after radiation therapy for head-and-neck cancer among a cohort of patients with human immunodeficiency virus (HIV). Methods and Materials: The medical records of 12 patients with serologic evidence of HIV who subsequently underwent radiation therapy to a median dose of 68 Gy (range, 64-72 Gy) for newly diagnosed squamous cell carcinoma of the head and neck were reviewed. Six patients (50%) received concurrent chemotherapy. Intensity-modulated radiotherapy was used in 6 cases (50%). All patients had a Karnofsky performance status of 80 or 90. Nine patients (75%) were receiving antiretroviral therapies at the time of treatment, and the median CD4 count was 460 (range, 266-800). Toxicity was graded according to the Radiation Therapy Oncology Group / European Organization for the Treatment of Cancer toxicity criteria. Results: The 3-year estimates of overall survival and local-regional control were 78% and 92%, respectively. Acute Grade 3+ toxicity occurred in 7 patients (58%), the most common being confluent mucositis (5 patients) and moist skin desquamation (4 patients). Two patients experienced greater than 10% weight loss, and none experienced more than 15% weight loss from baseline. Five patients (42%) experienced treatment breaks in excess of 10 cumulative days, although none required hospitalization. There were no treatment-related fatalities. Conclusions: Radiation therapy for head-and-neck cancer seems to be relatively well tolerated among appropriately selected patients with HIV. The observed rates of toxicity were comparable to historical controls without HIV.

KW - Head-and-neck cancer

KW - Human immunodeficiency virus

KW - Immunosuppression

KW - Radiotherapy

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=78649984338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649984338&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2009.10.042

DO - 10.1016/j.ijrobp.2009.10.042

M3 - Article

C2 - 20385454

AN - SCOPUS:78649984338

VL - 79

SP - 60

EP - 64

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -